United States Patent 9,833,448: What the Claims Cover and How the Landscape Maps
What is US Drug Patent 9,833,448 and what does claim 1 actually require?
US Patent 9,833,448 claims a method of treating migraine in a mammalian patient by administering a therapeutically effective amount of a pharmaceutical composition that contains a compound defined as “the compound of Formula II” (or a pharmaceutically acceptable salt).
Claim 1 (as provided):
- A method of treating migraine in a mammalian patient in need of such treatment, comprising:
- administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising
- the compound of Formula II, or a pharmaceutically acceptable salt thereof.
Claim scope elements created by this language
The claim is structured around four mandatory requirements:
| Claim element |
What it forces the invention to include |
Practical implication for scope |
| Disease indication |
“method of treating migraine” |
The therapeutic use must target migraine treatment, not a broader CNS condition unless migraine treatment is the clinical goal |
| Patient category |
“mammalian patient” |
Covers humans and non-human mammals (including preclinical species), though enforcement focus typically sits on human products |
| Dose and formulation |
“therapeutically effective amount” of “pharmaceutical composition” |
A product must be formulated and administered in an amount sufficient to treat migraine |
| Active identity |
“compound of Formula II” or a pharmaceutically acceptable salt |
Infringement depends on whether the administered active matches Formula II (or is the salt variant captured by the spec’s salt definition) |
Key constraint created by the claim
Claim 1 is a use claim tied to a specific chemical definition (Formula II). If a candidate drug does not read on Formula II (or the salt form), it does not meet the active-ingredient limitation as written.
What is the real claim coverage: broad use or narrow chemical lock-in?
Is this claim broad on indication but narrow on chemistry?
Yes. The indication is stated broadly as “migraine,” but the claim’s active ingredient is locked to Formula II.
Two-dimensional scope
1) Indication dimension (broad):
- “migraine” does not specify type (e.g., episodic vs chronic) or stage (acute vs prophylactic) in the claim language you provided.
2) Chemical dimension (narrow):
- The claim requires administration of the “compound of Formula II” (or a pharmaceutically acceptable salt).
- This means the claim boundary hinges on structure and salt identity, not just on migraine biology.
How “therapeutically effective amount” expands enforcement
Because the claim includes “therapeutically effective amount,” the patent does not require:
- a fixed dose range in the claim itself (unless the full specification ties the effective range to specific examples)
- a particular dosing schedule in the claim text provided
From a patent scope perspective, this term expands capture to any regimen that can be shown to be therapeutically effective for migraine, as long as the administered active meets Formula II and is delivered as a pharmaceutical composition.
What are the likely claim construction pressure points?
Even with only claim 1 provided, the text creates standard construction and evidentiary issues that drive validity and non-infringement analyses.
1) What counts as “compound of Formula II”?
The claim uses “the compound of Formula II,” which is typically a strict structural definition embedded in the patent drawings/text.
Infringement analysis typically turns on:
- Whether the candidate molecule is identical to the Formula II structure
- Whether the candidate is a defined salt of that compound that qualifies as “pharmaceutically acceptable”
2) What counts as a “pharmaceutically acceptable salt”?
This is usually determined by the specification’s salt list and general definition.
Enforcement and design-around often target:
- using a different chemical entity not captured by Formula II
- avoiding the salt forms recognized as pharmaceutically acceptable
- using prodrugs or different derivatives not reading on the defined Formula II compound as administered
3) Does the product have to be designed for migraine specifically?
The claim requires that the method is for treating migraine. For induced infringement (or method-of-use infringement), practical enforcement depends on the claim’s coupling to intended use and clinical activity.
If a candidate drug is used off-label for migraine, the method claim can still present risk depending on how the product is promoted and prescribed, but the patent text itself is still tied to the method of treating migraine.
4) Is “migraine” limited to specific subtypes in practice?
The claim text does not limit migraine subtype. If the specification supports multiple forms (acute attack treatment or prophylaxis), the broad wording can extend across subtypes. If the specification only supports one, the doctrine of claim scope and written description can constrain effective reach.
How does this patent fit into a typical US drug patent landscape?
What kind of patent is this, structurally?
Claim 1 is a method-of-treatment claim tied to a specific compound family (Formula II).
Landscape implication:
- This type of patent often shows up alongside other layers of patent protection for the same compound family:
- compound synthesis and composition claims (earlier)
- dosage regimen claims (subsequent)
- polymorph or salt forms (parallel)
- method claims for multiple indications (diversification risk for challengers)
Where the competitive pressure usually concentrates
When a company is developing a migraine drug with a potentially overlapping chemical series, infringement analysis centers on:
- structural match to Formula II
- salt selection strategy
- any claim scope arguments tied to migraine treatment efficacy and the “therapeutically effective amount” limitation
What would invalidate or narrow claim 1 in practice?
Without the specification and the full claim set, invalidity outcomes cannot be stated definitively. However, the claim’s structure indicates the main attack surfaces used in US practice.
1) Prior art on the same compound used for migraine
If the compound of Formula II (or its defined salt) was previously disclosed for migraine treatment, the method claim can be vulnerable to obviousness or anticipation arguments.
2) Prior art on the same use but different compound
If migraine methods and formulations were known but tied to different actives, challengers focus on whether the Formula II compound would have been obvious for migraine.
3) Enablement and written description tied to migraine
Because claim 1 recites migraine treatment, the specification must support treating migraine with the Formula II compound in a way that satisfies enablement and written description.
4) Claim clarity around Formula II scope
Formula II is determinative. If Formula II is broad, the written description may need to show the full scope works for migraine.
How can teams map competitors and design-arounds against claim 1?
A. Map chemical overlap first
The fastest way to assess risk is a structure-to-Formula-II comparison:
- Identify candidate actives (including salts and hydrates) intended for migraine treatment
- Check whether the marketed active is the exact Formula II compound or a salt form explicitly covered
- If the candidate is a prodrug or derivative, evaluate whether it converts in vivo into the Formula II compound that would be “administered” under a strict reading
B. Map formulation and administration
Claim 1 requires a “pharmaceutical composition.” If a competitor uses a non-pharmaceutical delivery format or a vehicle that is arguably not a pharmaceutical composition, it can create a construction dispute, though in modern drug practice this is rarely a clean design-around.
C. Map use and trial endpoints
Claim 1 requires migraine treatment. If a competitor’s clinical development never targets migraine (for example, targets a different headache disorder), method-of-use infringement risk changes. If migraine is targeted in trials, risk increases.
Claim 1 coverage summary (scope ledger)
| Coverage bucket |
What is captured |
What is not captured (based on claim text alone) |
| Active identity |
Formula II compound and pharmaceutically acceptable salts |
Non-Formula II compounds and salts not recognized as pharmaceutically acceptable |
| Indication |
“migraine” |
Other headache disorders not characterized as migraine unless migraine is the intended treated condition |
| Method |
Administer therapeutically effective amount in a pharmaceutical composition |
Fixed-dose regimen not required by claim text (unless the full spec narrows scope) |
| Patient population |
mammalian patients |
Non-mammalian conditions (not relevant for human drugs) |
What is missing from the claim text and why it matters for a complete landscape
A complete patent landscape for US 9,833,448 requires the elements below, because they determine:
- exact structure of Formula II
- the full claim set (narrower dependent claims often define dose/salt/administration route)
- priority dates and prosecution history (affects obviousness/novelty threats)
- related patents and continuation family members (affects freedom-to-operate timeline)
However, those data are not present in the input provided.
Key Takeaways
- Claim 1 is an indication-linked method claim for migraine that requires administration of a therapeutically effective amount of a pharmaceutical composition containing the specific compound defined as “Formula II” (or its pharmaceutically acceptable salts).
- The claim’s indication language is broad, but the chemical limitation is the primary scoping boundary. Freedom-to-operate is most sensitive to whether a candidate active matches Formula II and whether the administered form is a captured salt.
- Practical infringement and design-around efforts should prioritize structure-to-Formula-II matching and salt/form selection, then evaluate migraine-focused use and therapeutic effectiveness in dosing regimens.
FAQs
1) Does claim 1 require a specific dose or regimen?
Claim 1 requires a “therapeutically effective amount” but does not specify a dose range or schedule in the provided text, so the regimen can vary as long as it is therapeutically effective for migraine.
2) Can a different salt of the Formula II compound avoid infringement?
If the salt is still a “pharmaceutically acceptable salt” of the Formula II compound, it falls within the claim text. Avoidance typically depends on whether the salt form is excluded by the patent’s salt definition or is not considered pharmaceutically acceptable under the claim construction.
3) Is the claim limited to humans?
No. The claim covers “a mammalian patient,” which includes humans and other mammals.
4) Is migraine limited to a specific subtype (acute vs prophylactic)?
The claim text provided does not specify a subtype. Scope in practice depends on how migraine is supported and defined across the patent’s specification and dependent claims.
5) What is the fastest non-infringement path?
A candidate must avoid meeting the active limitation. The most direct path is to ensure the administered active is not the Formula II compound (and not a covered salt form).
References
[1] US Patent 9,833,448, claim 1 (method of treating migraine; administering pharmaceutical composition comprising compound of Formula II or pharmaceutically acceptable salt).
